BC Week In Review | Feb 29, 2016
Clinical News

Dapivirine Vaginal Ring: Phase III data

Top-line data from the double-blind, South African and Ugandan Phase III Ring Study in 1,959 HIV-negative women ages 18-45 showed that a once-monthly vaginal ring containing 25 mg dapivirine reduced the incidence of HIV infection...
BC Week In Review | Feb 29, 2016
Clinical News

Dapivirine Vaginal Ring: Phase III data

Top-line data from the double-blind Phase III ASPIRE trial in 2,629 HIV-negative women ages 18-45 in Malawi, South Africa, Uganda and Zimbabwe showed that a once-monthly vaginal ring containing 25 mg dapivirine reduced the incidence...
BC Week In Review | May 12, 2014
Company News

J&J, International Partnership for Microbicides deal

Johnson & Johnson's Janssen R&D Ireland unit granted the not-for-profit exclusive, worldwide rights to develop and commercialize dapivirine under an expanded 2004 deal. IPM gained a royalty-free license to the dianilinopyrimidine derivative in developing countries...
BC Week In Review | Jun 14, 2010
Clinical News

Dapivirine: Phase I/II started

The International Partnership for Microbicides began a placebo-controlled, African Phase I/II (IPM 015) trial to evaluate a dapivirine vaginal ring in 280 women. The ring releases 25 mg dapivirine over 28 days. The non-profit organization...
BC Innovations | May 21, 2009
Targets & Mechanisms

Circle of protection against HIV

New in vitro research suggests that HIV infection can be prevented by inducing the endogenous production of θ-defensins, a class of cyclic antimicrobial peptides whose expression is thought to be blocked in the vast majority...
BC Innovations | Apr 23, 2009
Cover Story

Topical ideas for HIV

Two studies propose the use of known compounds to block HIV at the vaginal epithelium, the most common site of initial infection. The compounds, glycerol monolaurate, a mild surfactant, and griffithsin, an algal protein, showed...
BC Innovations | Feb 14, 2008
Cover Story

New roadblock to HIV infection

The goal of developing an effective vaginal microbicide against HIV infection has eluded researchers ever since the first potential compound assessed, nonoxynol-9, proved to actually increase infection rates. In the Proceedings of the National Academy...
BC Week In Review | Apr 5, 2004
Company News

J&J, International Partnership for Microbicides deal

IPM received a royalty-free license from JNJ subsidiary Tibotec Pharmaceuticals Ltd. (Mechelen, Belgium) to develop, manufacture and distribute in "resource poor countries" TMC120 , a topical non-nucleoside reverse transcriptase inhibitor to protect women from HIV infection....
BC Week In Review | Feb 12, 2001
Clinical News

TMC120: Phase I/II

Tibotec reported that in a Phase I/II trial of 43 patients with HIV, 50 or 100 mg of TMC120 given twice daily for 7 days was safe. At the low dose, the number of copies/ml...
BC Extra | Feb 9, 2001
Clinical News

Tibotec Phase II HIV data

Tibotec (Mechelen, Belgium) said that in a double-blind, placebo-controlled Phase II study in 43 treatment-naive HIV patients, its TMC120 non-nucleoside reverse transcriptase inhibitor gave a mean 1.51 log reduction in viral load after one week....
Items per page:
1 - 10 of 10